Search
Celularity Inc
CELUAdd to Watchlist
0.604USD
+0.006+1.07%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
17.43MMarket Cap
LossP/E TTM
More Details of Celularity Inc Company
Celularity Inc. is a regenerative and cellular medicine company. The Company is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells, T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. It develops, manufactures and commercializes advanced biomaterial products derived from structural tissue components of the postpartum placental tissues, including the umbilical cord. Its advanced biomaterials include Celularity Tendon Wrap, FUSE Bone Void Filler and Celularity Placental Matrix. Its advanced biomaterial products include Biovance, Biovance 3L, CentaFlex, Interfyl and Rebound products.
Celularity Inc Info
Ticker SymbolCELU
Company nameCelularity Inc
IPO dateMay 23, 2019
CEOHariri (Robert J)
Number of employees123
Security typeOrdinary Share
Fiscal year-endMay 23
Address170 Park Ave
CityFLORHAM PARK
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code07932
Phone19087682170
Websitehttps://celularity.com/
Ticker SymbolCELU
IPO dateMay 23, 2019
CEOHariri (Robert J)
Company Executives of Celularity Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
2.86M
+0.07%
Mr. Vincent Levien
Mr. Vincent Levien
Independent Director
Independent Director
157.55K
+18.31%
Dr. Peter H. Diamandis, M.D.
Dr. Peter H. Diamandis, M.D.
Independent Director
Independent Director
--
--
Ms. Diane L. Parks
Ms. Diane L. Parks
Independent Director
Independent Director
--
--
Mr. Stephen A. Brigido
Mr. Stephen A. Brigido
President - Degenerative Disease
President - Degenerative Disease
--
--
Mr. John R. Haines
Mr. John R. Haines
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
--
--
Dr. Shiu Fei (Geoffrey) Ling, M.D., Ph.D.
Dr. Shiu Fei (Geoffrey) Ling, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Carlos Ramirez
Mr. Carlos Ramirez
Senior Vice President - Investor Relations
Senior Vice President - Investor Relations
--
--
Mr. Joseph Dossantos
Mr. Joseph Dossantos
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
2.86M
+0.07%
Mr. Vincent Levien
Mr. Vincent Levien
Independent Director
Independent Director
157.55K
+18.31%
Dr. Peter H. Diamandis, M.D.
Dr. Peter H. Diamandis, M.D.
Independent Director
Independent Director
--
--
Ms. Diane L. Parks
Ms. Diane L. Parks
Independent Director
Independent Director
--
--
Mr. Stephen A. Brigido
Mr. Stephen A. Brigido
President - Degenerative Disease
President - Degenerative Disease
--
--
Mr. John R. Haines
Mr. John R. Haines
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
--
--
FAQs
Who are the top five shareholders of Celularity Inc?
The top five shareholders of Celularity Inc are: Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
How many institutions hold shares of Celularity Inc (CELU)?
As of 2026Q1, 64 institutions hold shares of Celularity Inc, with a combined market value of approximately 3.75M, accounting for 12.95% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -258480.00.